TY - JOUR
T1 - Synthesis and biological evaluation of a focused library of beauveriolides
AU - Nagai, Kenichiro
AU - Doi, Takayuki
AU - Ohshiro, Taichi
AU - Sunazuka, Toshiaki
AU - Tomoda, Hiroshi
AU - Takahashi, Takashi
AU - Omura, Satoshi
N1 - Funding Information:
This work was supported by the Program for Promotion of Fundamental Studies in Health Sciences of the National Institute of Biomedical Innovation (NIBIO), by grant-in-aid for Scientific Research (B) 18390008 (H.T.) and Scientific Research on Priority Areas 18032028 (T.D.) from the Ministry of Education, Culture, Sports, Science and Technology, Japan, and by the Hoh-ansya Foundation, Japan.
PY - 2008/8/1
Y1 - 2008/8/1
N2 - Fungal beauveriolide III (1b), discovered as an inhibitor of lipid droplet accumulation in mouse macrophages and showing antiatherogenic activity in mouse model, consists of l-Phe, l-Ala, d-allo-Ile, and (3S, 4S)-3-hydroxy-4-methyloctanoic acid moieties. A combinatorial library of beauveriolide analogues focusing on l-Ala and d-allo-Ile of 1b was synthesized by combinatorial synthesis. Among them, d-Ala analogues consisting of A{2} improved their solubility, while those with 7{1, 3, 2},7{2, 3, 1}, and 7{2, 3, 2} were 20 times more potent than 1b.
AB - Fungal beauveriolide III (1b), discovered as an inhibitor of lipid droplet accumulation in mouse macrophages and showing antiatherogenic activity in mouse model, consists of l-Phe, l-Ala, d-allo-Ile, and (3S, 4S)-3-hydroxy-4-methyloctanoic acid moieties. A combinatorial library of beauveriolide analogues focusing on l-Ala and d-allo-Ile of 1b was synthesized by combinatorial synthesis. Among them, d-Ala analogues consisting of A{2} improved their solubility, while those with 7{1, 3, 2},7{2, 3, 1}, and 7{2, 3, 2} were 20 times more potent than 1b.
KW - ACAT
KW - Antiatherogenic activity
KW - Cyclic depsipeptide
KW - Focused library
UR - http://www.scopus.com/inward/record.url?scp=47749149909&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=47749149909&partnerID=8YFLogxK
U2 - 10.1016/j.bmcl.2008.06.054
DO - 10.1016/j.bmcl.2008.06.054
M3 - Article
C2 - 18620856
AN - SCOPUS:47749149909
SN - 0960-894X
VL - 18
SP - 4397
EP - 4400
JO - Bioorganic and Medicinal Chemistry Letters
JF - Bioorganic and Medicinal Chemistry Letters
IS - 15
ER -